.jpg?w=340&itok=bVLWHHAG "EPR in healthcare news."){kind=icon}
.jpg?w=340&itok=t0Ej5FUA "EPR in healthcare news."){kind=icon}
With ADC innovation accelerating across Asia, Europe and the US, regulatory synchronisation has never been more important. ICON’s latest article in BioSpectrum Asia explores why proactive scientific advice, dose optimis...
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From biopsy bottlenecks to biomarker breakthroughs - how non-invasive tools are reshaping MASH trials
This article examines how non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. It also outlines the rapidly evolving NIT landscape, emerging regulatory perspectives, and key opportunities to optimise MASH trial design and execution.
-
.jpg?w=545&itok=913nO6vx "EPR in healthcare news.")
The move to greener clinical development
Sustainability requires a layered approach that balances operational feasibility and with greener practices. Sean Morgan, Director of Clinical Supplies Management, discusses how ICON is tackling issues like kit waste, carbon emissions and ethical supply chains.
-
ICON’s advances on the perpetual path of innovation in laboratory solutions
Innovative laboratory solutions have the potential to optimise clinical research processes, create more efficient operations and improve sustainability to support wider organisational objectives. In this article published by R&D World, ICON outlines some of the new initiatives that are in progress to ensure the continued delivery of high quality results that meet sponsors’ needs – today and tomorrow.
-
.jpg?w=545&itok=7TwTSGBt "EPR in healthcare news.")
Application of NGS to enhance the molecular monitoring of CML patients
This Q&A with Dr Jin Li and Dr Chad Galderisi of ICON Specialty Laboratory Solutions discusses ICON’s development of its RNA-based next generation sequencing (NGS) assay that detects mutations in chronic myeloid leukemia (CML) and how it can benefit both routine clinics and clinical trial settings.
-
Outsourcing analytical testing: AI could transform analytical labs
In this article from Drug Development & Delivery, Suzanne Jansen, Head of QC Laboratory, discusses the importance of faster data turnaround within the analytical lab to facilitate adaptive dosing decisions that will benefit all stages of clinical trials.
-
Driving progress in reducing kit wastage
In this article from European Pharmaceutical Manufacturer,Leonard Wee, VP, Global Supply Chain, Laboratories, explores how shifting to more reliable kit forecasting, in tandem with efficient kit building practices, can help reduce waste, cost and logistical requirements.
-
Beyond the glass: A look at digital pathology’s practical applications and novel possibilities in clinical trials
In this article from Diagnostics World News, Jenny Ross, Pathologist and Medical Director, looks at practical uses of digital pathology technologies and illustrates considerations for their use in global clinical trials.
-
Innovative laboratory testing methods for clinical monitoring of cell therapies using flow cytometry DDPCR and QPCR assays
In this article from International Biopharmaceutical Industry, Dr. Chad Galderisi, Vice President and Global Medical Director for ICON Specialty Laboratories explores how unique applications of PCR and flow cytometry can be used to provide critical and complementary data that is needed to bring new life-saving treatment options to patients.
Published by International Biopharmaceutical Industry Journal Volume 6 Issue 3
-
Bioanalytical outsourcing soars as drugs grow more complex
Radboud van Trigt, Senior Director of Bioanalytical Science, contributes to this article in Contract Pharma that looks at trends in bioanalytic outsourcing against the backdrop of the increasingly complex nature of modern-day therapeutics.
-
The personalised medicine paradigm
Cindy Spittle shares insights on the growth of molecular diagnostic testing in clinical trials.
